{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:47:33Z","timestamp":1765889253096,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"DOI":"10.1093\/ehjcvp\/pvae005","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T04:26:03Z","timestamp":1708143963000},"page":"83-84","source":"Crossref","is-referenced-by-count":3,"title":["New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-6312","authenticated-orcid":false,"given":"Stefan","family":"Agewall","sequence":"first","affiliation":[{"name":"Institute of Clinical Sciences, Karolinska Institute of Danderyd , Stockholm \u00a0 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024022306031996200_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ehjcvp\/pvac043","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus","volume":"9","author":"Eroglu","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","article-title":"Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence","volume":"8","author":"Aguilar-Gallardo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024022306031996200_bib4","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/ehjcvp\/pvab008","article-title":"Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Lombardi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib5","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"key":"2024022306031996200_bib6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease","volume":"34","author":"Nordstrom","year":"2013","journal-title":"Eur Heart J"},{"key":"2024022306031996200_bib7","doi-asserted-by":"crossref","first-page":"15451","DOI":"10.1038\/srep15451","article-title":"Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"2024022306031996200_bib8","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1093\/ehjcvp\/pvab081","article-title":"Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021","volume":"8","author":"Mone","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ehjcvp\/pvac064","article-title":"Initial statin dose after myocardial infarction and long-term cardiovascular outcomes","volume":"9","author":"Kyt\u00f6","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ehjcvp\/pvab026","article-title":"Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis","volume":"8","author":"Thangjui","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients","volume":"8","author":"Chen","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ehjcvp\/pvac060","article-title":"Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: observations from the prospective EMIR Registry","volume":"9","author":"Esteve-Pastor","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib14","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a hospital frailty risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"2024022306031996200_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","article-title":"Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence","volume":"8","author":"Aguilar-Gallardo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ehjcvp\/pvab088","article-title":"Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis","volume":"8","author":"Ameri","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","article-title":"Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?","volume":"7","author":"Ameri","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024022306031996200_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ehjcvp\/pvac040","article-title":"Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae005\/56682984\/pvae005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/2\/83\/56714912\/pvae005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/2\/83\/56714912\/pvae005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:09:14Z","timestamp":1708668554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/2\/83\/7608607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae005","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"type":"print","value":"2055-6837"},{"type":"electronic","value":"2055-6845"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,15]]}}}